Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 10

PMID 35267426

Authors

Francesca Lorenzin

Francesca Demichelis

Affiliations

Soon will be listed here.

Abstract

The ETS family member ERG is a transcription factor with physiological roles during development and in the vascular and hematopoietic systems. ERG oncogenic activity characterizes several malignancies, including Ewing's sarcoma, leukemia and prostate cancer (PCa). In PCa, rearrangements with androgen-regulated genes-mostly -characterize a large subset of patients across disease progression and result in androgen receptor (AR)-mediated overexpression of ERG in the prostate cells. Importantly, PCa cells overexpressing ERG are dependent on ERG activity for survival, further highlighting its therapeutic potential. Here, we review the current understanding of the role of ERG and its partners in PCa. We discuss the strategies developed in recent years to inhibit ERG activity, the current therapeutic utility of ERG fusion detection in PCa patients, and the possible future approaches to target ERG fusion-positive tumors.

Citing Articles

SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance.

Wei G, Huang Y, Li W, Xie Y, Zhang D, Niu Y Cell Death Discov. 2025; 11(1):75.

PMID: 39988626 PMC: 11847930. DOI: 10.1038/s41420-025-02354-7.

Advancements in Biomarkers of Prostate Cancer: A Review.

Agbetuyi-Tayo P, Gbadebo M, Rotimi O, Rotimi S Technol Cancer Res Treat. 2024; 23:15330338241290029.

PMID: 39440372 PMC: 11497500. DOI: 10.1177/15330338241290029.

TMPRSS2::ETS translocation in nonprostatic malignancies: an unexpected finding in thymic carcinoma and pulmonary adenocarcinoma.

Nemeth K, Bathory-Fulop L, Kohanka A, Simon A, Toth E, Melegh Z Virchows Arch. 2024; .

PMID: 39283524 DOI: 10.1007/s00428-024-03927-0.

Elevated LAMTOR4 Expression Is Associated with Lethal Prostate Cancer and Its Knockdown Decreases Cell Proliferation, Invasion, and Migration In Vitro.

Gamallat Y, Alwazan H, Turko R, Dang V, Seyedi S, Ghosh S Int J Mol Sci. 2024; 25(15).

PMID: 39125671 PMC: 11312415. DOI: 10.3390/ijms25158100.

Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases.

Zhang Y, Zhang Y, Shi M, Liu X, Zhang H, Zhao P Am J Clin Exp Urol. 2024; 12(2):100-109.

PMID: 38736618 PMC: 11087209. DOI: 10.62347/XOIN3964.

References

Mounir Z, Korn J, Westerling T, Lin F, Kirby C, Schirle M . ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor. Elife. 2016; 5. PMC: 4909395. DOI: 10.7554/eLife.13964. View

Eldhose B, Pandrala M, Xavier C, Mohamed A, Srivastava S, Sunkara A . New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives. ACS Med Chem Lett. 2021; 12(11):1703-1709. PMC: 8591719. DOI: 10.1021/acsmedchemlett.1c00308. View

Mounir Z, Lin F, Lin V, Korn J, Yu Y, Valdez R . TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 2014; 34(29):3815-25. DOI: 10.1038/onc.2014.308. View

Shukla S, Cyrta J, Murphy D, Walczak E, Ran L, Agrawal P . Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017; 32(6):792-806.e7. PMC: 5728174. DOI: 10.1016/j.ccell.2017.10.008. View

Leyten G, Hessels D, Jannink S, Smit F, de Jong H, Cornel E . Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012; 65(3):534-42. DOI: 10.1016/j.eururo.2012.11.014. View

Tsuzuki S, Taguchi O, Seto M . Promotion and maintenance of leukemia by ERG. Blood. 2011; 117(14):3858-68. DOI: 10.1182/blood-2010-11-320515. View

Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L . SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest. 2017; 128(1):381-386. PMC: 5749531. DOI: 10.1172/JCI96551. View

Hussain M, Daignault-Newton S, Twardowski P, Albany C, Stein M, Kunju L . Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2017; 36(10):991-999. PMC: 6075827. DOI: 10.1200/JCO.2017.75.7310. View

McLaughlin F, Ludbrook V, Cox J, von Carlowitz I, Brown S, Randi A . Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation. Blood. 2001; 98(12):3332-9. DOI: 10.1182/blood.v98.12.3332. View

10.

Cai C, Wang H, He H, Chen S, He L, Ma F . ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013; 123(3):1109-22. PMC: 3582143. DOI: 10.1172/JCI66666. View

11.

Teply B, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A . Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2017; 19(1):76-86. PMC: 5875180. DOI: 10.1016/S1470-2045(17)30906-3. View

12.

Wang S, Kollipara R, Humphries C, Ma S, Hutchinson R, Li R . The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer. Oncotarget. 2016; 7(40):64921-64931. PMC: 5323126. DOI: 10.18632/oncotarget.11915. View

13.

Birdsey G, Dryden N, Shah A, Hannah R, Hall M, Haskard D . The transcription factor Erg regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood. 2011; 119(3):894-903. DOI: 10.1182/blood-2011-04-350025. View

14.

Fraser M, Sabelnykova V, Yamaguchi T, Heisler L, Livingstone J, Huang V . Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017; 541(7637):359-364. DOI: 10.1038/nature20788. View

15.

Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

16.

Karim F, Urness L, Thummel C, Klemsz M, McKercher S, Celada A . The ETS-domain: a new DNA-binding motif that recognizes a purine-rich core DNA sequence. Genes Dev. 1990; 4(9):1451-3. DOI: 10.1101/gad.4.9.1451. View

17.

Yuan L, Nikolova-Krstevski V, Zhan Y, Kondo M, Bhasin M, Varghese L . Antiinflammatory effects of the ETS factor ERG in endothelial cells are mediated through transcriptional repression of the interleukin-8 gene. Circ Res. 2009; 104(9):1049-57. PMC: 3896055. DOI: 10.1161/CIRCRESAHA.108.190751. View

18.

Tomlins S, Mehra R, Rhodes D, Cao X, Wang L, Dhanasekaran S . Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2006; 39(1):41-51. DOI: 10.1038/ng1935. View

19.

Laxman B, Tomlins S, Mehra R, Morris D, Wang L, Helgeson B . Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia. 2006; 8(10):885-8. PMC: 1715928. DOI: 10.1593/neo.06625. View

20.

Annala M, Struss W, Warner E, Beja K, Vandekerkhove G, Wong A . Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017; 72(1):34-42. DOI: 10.1016/j.eururo.2017.02.023. View